Загрузка...
Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...
Сохранить в:
| Опубликовано в: : | Diabetes Obes Metab |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Blackwell Publishing Ltd
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5067686/ https://ncbi.nlm.nih.gov/pubmed/26663320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12621 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|